People with HIV aged 75 and older receiving good HIV care but many at risk of frailty

People with HIV aged 75 years and older are receiving “almost perfectly managed” care, but are more likely to experience age-related health conditions, according to French research published in Médecine et maladies infectieuses.

Read More

Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?

People who switched from Truvada (tenofovir disoproxil fumarate/emtricitabine) to the newer Descovy (tenofovir alafenamide/emtricitabine) for pre-exposure prophylaxis (PrEP) experienced improvements in measures of kidney function and bone density, but adverse clinical outcomes were rare with either coformulation, researchers reported at the recent IDWeek 2019 conference in Washington, DC.

Read More